Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mandibular Splint vs Botox in TMD
NCT06553950Recruiting
- Sponsor
- Cairo University
- Start
- Aug 2024
- Primary completion
- Feb 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of botulinum toxin type A in temporomandibular disorders (TMD) (3 arms), sponsored by Cairo University. Primary endpoint: Muscle activity of upper trapezius and sternocleidomastoid at 3 months. Started Aug 2024; status: recruiting.
02
Drugs
botulinum toxin type A
03
Conditions
temporomandibular disorders (TMD)
Beyond the preview
Go deeper on NCT06553950.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06553950.